[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354963-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-354963-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","surgical-cytoreduction-versus-systemic-therapy-in-patients-with-metastatic-gastroenteropancreatic-neuroendocrine-neoplasms-gep-nens-a-national-cancer-database-analysis-ncdb","Surgical cytoreduction versus systemic therapy in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENS) - a national cancer database analysis (NCDB)","","Using data from the National Cancer Database (2004–2020), this original research evaluates overall survival associated with cytoreductive surgery versus systemic therapy alone in adults with stage IV well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). The study compares treatment cohorts using Kaplan–Meier analysis and multivariable Cox proportional hazards models. Median overall survival favored cytoreductive surgery, with benefits persisting across histologic grades and primary tumor sites, while delayed surgery (>35 days) and favorable selection factors were linked to improved outcomes.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/surgical-cytoreduction-versus-systemic-therapy-in-patients-with-metastatic-gastroenteropancreatic-neuroendocrine-neoplasms-gep-nens-a-national-cancer-database-analysis-ncdb/354963/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/surgical-cytoreduction-versus-systemic-therapy-in-patients-with-metastatic-gastroenteropancreatic-neuroendocrine-neoplasms-gep-nens-a-national-cancer-database-analysis-ncdb/354963.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about metastatic GEP-NENs?","Question",{"text":63,"@type":64},"It evaluates the optimal role of surgical cytoreduction by comparing overall survival from cytoreductive surgery versus systemic therapy alone in metastatic GEP-NENs.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were treatments compared in the National Cancer Database analysis?",{"text":68,"@type":64},"Patients were grouped into cytoreductive surgery (CRS) alone, CRS plus systemic chemotherapy, and systemic therapy alone, then compared using Kaplan–Meier analysis and multivariable Cox models.",{"name":70,"@type":61,"acceptedAnswer":71},"What overall survival differences were observed between treatment groups?",{"text":72,"@type":64},"Median overall survival was 140.9 months for CRS alone, 96.2 months for CRS plus chemotherapy, and 51.6 months for systemic therapy alone, with statistically significant differences.",{"name":74,"@type":61,"acceptedAnswer":75},"Did the survival benefit of CRS remain consistent across tumor subgroups?",{"text":76,"@type":64},"Yes. The survival advantage persisted across histologic grades and primary tumor sites, and CRS remained independently associated with improved overall survival in multivariable analysis.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},354963,1790187180,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,104,109,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},"Comic",60,"comic",{"id":105,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},6,"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},7,"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":55,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","TYPE Original Research PUBLISHED 14 January 2026 DOI 10.3389/or.2025.1589775  \nOPEN ACCESS  \nEDITED BY  \nEvan Vosburgh,  \nUnited States Department of Veterans Affairs, United States  \nREVIEWED BY  \nAnna La Salvia,  \nNational Institute of Health (ISS), Italy Alberto Bongiovanni,  \nUniCamillus-Saint Camillus International University of Health and Medical Sciences, Italy Marie Louise Ndzie Noah,  \nShandong First Medical University, China Zhengqi Wu,  \nThird Affiliated Hospital of Sun Yat-sen University, China  \n*CORRESPONDENCE  \nAmr Mohamed,  \n [amr.mohamed@uhhospitals.org](amr.mohamed@uhhospitals.org)  \nRECEIVED 07 March 2025  \nREVISED 28 November 2025  \nACCEPTED 19 December 2025  \nPUBLISHED 14 January 2026  \nCITATION  \nMohamed A, Ahmed FA, Pawar O, Lal T, Winter J, Ammori J, Hardacre J, Mahipal A, Bajor D, Chakrabarti S, Asa S, Selfridge E, Conces M, Lumish M, Tirumani S, Henke L and Hoehn R (2026) Surgical cytoreduction versus systemic therapy in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENS): a national cancer database analysis (NCDB) .  \nOncol. Rev. 19:1589775 .  \ndoi: 10.3389/or.2025.1589775  \nCOPYRIGHT  \n© 2026 Mohamed, Ahmed, Pawar, Lal, Winter, Ammori, Hardacre, Mahipal, Bajor, Chakrabarti, Asa, Selfridge, Conces, Lumish, Tirumani, Henke and Hoehn. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nSurgical cytoreduction versus systemic therapy in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENS): a national cancer database analysis (NCDB)  \nAmr Mohamed 1*, Fasih A. Ahmed 2,3, Omkar Pawar 2, Trisha Lal 2, Jordan Winter 2, John Ammori 2, Jeffrey Hardacre 2,  \nAmit Mahipal 1, David Bajor 1, Sakti Chakrabarti 1, Sylvia Asa 4, Eva Selfridge 1, Madison Conces 1, Melissa Lumish 1,  \nSree Tirumani 5, Lauren Henke 6 and Richard Hoehn 2  \n1Department of Medicine, Division of Hematology and Medical Oncology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, United States, 2Department of Surgical Oncology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, United States, 3Department of Surgery, Stanford University School of Medicine, Palo Alto, CA, United States, 4Department of Pathology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, United States, 5Department of Radiology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, United States, 6Department of Radiation Oncology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, United States  \nBackground: The optimal role of surgical cytoreduction in metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) remains uncertain, as supporting evidence is largely retrospective and rarely compares surgery with contemporary systemic therapy. Using a national cancer registry, we evaluated overall survival (OS) associated with cytoreductive surgery compared with systemic therapy alone.  \nMethods: Adult patients with stage IV well-differentiated GEP-NENs were identified in the National Cancer Database (2004–2020) . Demographic, tumor, and facility variables stratified patients. Treatment groups included cytoreductive surgery (CRS) alone, CRS plus systemic chemotherapy, and systemic therapy alone. Overall survival (OS) was compared using KaplanMeier (KM) analysis and multivariable Cox proportional hazards models. Results: Among 3,183 patients with stage IV GEP-NENs, 69. 8% underwent cytoreductive surgery (CRS)","cbCaiaCyW3O7zZn8","https://ap.wps.com/l/cbCaiaCyW3O7zZn8","pdf",2325179,"English","# Background\n## Methods and patient selection\n## Results: survival comparisons\n## Multivariable findings\n## Conclusion and implications","[{\"question\":\"What question does the study address about metastatic GEP-NENs?\",\"answer\":\"It evaluates the optimal role of surgical cytoreduction by comparing overall survival from cytoreductive surgery versus systemic therapy alone in metastatic GEP-NENs.\"},{\"question\":\"How were treatments compared in the National Cancer Database analysis?\",\"answer\":\"Patients were grouped into cytoreductive surgery (CRS) alone, CRS plus systemic chemotherapy, and systemic therapy alone, then compared using Kaplan–Meier analysis and multivariable Cox models.\"},{\"question\":\"What overall survival differences were observed between treatment groups?\",\"answer\":\"Median overall survival was 140.9 months for CRS alone, 96.2 months for CRS plus chemotherapy, and 51.6 months for systemic therapy alone, with statistically significant differences.\"},{\"question\":\"Did the survival benefit of CRS remain consistent across tumor subgroups?\",\"answer\":\"Yes. The survival advantage persisted across histologic grades and primary tumor sites, and CRS remained independently associated with improved overall survival in multivariable analysis.\"}]","Surgical cytoreduction versus systemic therapy in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENS) - a national cancer database analysis (NCDB) | PDF",1790115099,25,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64a095b384fa11200e3e4eedae400773.webp",983,1390,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1d1ec0cb80df8c856ab0ed627dd8a9d.webp",982,1388,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99f5f0fb562c7bfc6268b2a9143e74c3.webp",981,1387,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08a49d87fb932789521ef6b5b025e39c.webp",980,1385]